Zyrova 40 Tablet

Rosuvastatin acts by selectively inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby decreasing cholesterol production in the liver and enhancing the clearance of LDL particles from the bloodstream. Zyrova 40 is prescribed to patients at high risk of cardiovascular events, including those with a history of coronary artery disease, stroke, or peripheral arterial disease, as part of a comprehensive management plan involving diet, exercise, and lifestyle modifications.

The tablet should be taken orally once daily, with or without food, preferably at the same time each day. Common adverse effects may include headache, myalgia, abdominal pain, and nausea; however, serious side effects such as rhabdomyolysis and hepatotoxicity are rare but require immediate medical attention. Regular monitoring of liver function tests and creatine kinase levels is recommended during therapy.

Zyrova 40 should be used with caution in patients with pre-existing liver or kidney conditions and is contraindicated during pregnancy and lactation.